About the journal
Nature Cancer is a journal published by Nature Portfolio in United States. It is listed in MEDLINE and PUBMED according to the sources read. Declared publication charge: 11,690 EUR. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- Nature Portfolio
- ISSN
- 2662-1347
- Country
- United States
- Access
- Not open access / not declared
- Declared publication charge
- 11,690 EUR
- Declared peer-review model
- peer_review
- Official website
- https://www.nature.com/natcancer/
Index listings
- MEDLINE · 2020-01-01
- PUBMED · 2025-11-01
- Indexing
- MEDLINE · PUBMED
- APC
- 11,690 EUR
- Declared review time (DOAJ)
- —
- Actual review time (measured)
- 328 days received→accepted — computed from PubMed (n=56)
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Works in OpenAlex
1191
Last recorded publication year
2026
h-index
129
i10-index
588
From OpenAlex open data (CC0).
Editorial & policy5
- Observed digital preservation (Keepers registry)— snapshot 2026-10-05
- CLOCKSSPortico
- Norwegian register (HK-dir)— 2027
- Level 2 — top tier (~20% of the field's channels)
- Open references deposited at Crossref
- 84%
- ORCID iDs in current deposits
- 77%
- Enrolled in Crossref Similarity Check
- ✓
- Deposits licence metadata at Crossref
- ✓
Identity & continuity2
- Source type
- journal
- NLM unique ID (PubMed)
- 101761119
Classification(no data)
No data available to the platform for this group
No platform data for: Classification — absence is not a judgment about the journal.
Subject areas
- Cancer Immunotherapy and Biomarkers
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Cancer Genomics and Diagnostics
- CAR-T cell therapy research
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Immunotherapy and Immune Responses
Show all subjects (50)
- Immune Cell Function and Interaction
- Immune Cell Function and Interaction
- Immune cells in cancer
- Immune cells in cancer
- Epigenetics and DNA Methylation
- Epigenetics and DNA Methylation
- Cancer Cells and Metastasis
- Cancer Cells and Metastasis
- RNA modifications and cancer
- RNA modifications and cancer
- Cancer, Hypoxia, and Metabolism
- Glioma Diagnosis and Treatment
- Glioma Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Single-cell and spatial transcriptomics
- Single-cell and spatial transcriptomics
- Lung Cancer Treatments and Mutations
- Lung Cancer Treatments and Mutations
- Pancreatic and Hepatic Oncology Research
- Pancreatic and Hepatic Oncology Research
- Ferroptosis and cancer prognosis
- Ferroptosis and cancer prognosis
- Acute Myeloid Leukemia Research
- Acute Myeloid Leukemia Research
- Protein Degradation and Inhibitors
- Protein Degradation and Inhibitors
- Cancer Research and Treatments
- T-cell and B-cell Immunology
- T-cell and B-cell Immunology
- Cancer Research and Treatments
- AI in cancer detection
- Monoclonal and Polyclonal Antibodies Research
- Monoclonal and Polyclonal Antibodies Research
- AI in cancer detection
- Radiomics and Machine Learning in Medical Imaging
- Radiomics and Machine Learning in Medical Imaging
- PARP inhibition in cancer therapy
- Lung Cancer Research Studies
- Lung Cancer Research Studies
- PARP inhibition in cancer therapy
- Prostate Cancer Treatment and Research
- Prostate Cancer Treatment and Research
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
The journal's record in other sources:Web of Science MJLDOAJ